The brief viability of organs creates a logistical nightmare. Surgeons fly on chartered jets to retrieve organs, while recipients must remain within a small radius of the hospital, unable to travel. Cryopreservation's immediate impact would be to remove time as a variable, allowing for scheduled surgeries and a more humane patient experience.

Unlike external machines, implanting parts internally triggers the body's powerful defenses. The immune system attacks foreign objects, and blood forms clots around non-native surfaces. These two biological responses are the biggest design hurdles for internal replacement parts, problems that external devices like dialysis machines don't face.

The "replacement strategy" for longevity analogizes the body to a complex machine like an iPhone. It's often impossible to fix a shattered screen (a failing organ), but swapping the part is simple and effective. This reframes the approach to thousands of "incurable" diseases from repair to replacement.

A major unknown was the surgical procedure itself. After four cases, surgeons report that transplanting a pig kidney is remarkably similar to a human-to-human allogeneic transplant. This de-risks the surgical component significantly, with patients often leaving the ICU in one night.

The FDA's traditional focus on risk avoidance overlooks the inherent risk of delay. Unnecessary bureaucratic steps, like months of animal trials, prevent dying patients from accessing potentially life-saving treatments. The cost of inaction is measured in lives lost.

The initial, highly valuable application for reversible organ cryopreservation is not futuristic hibernation but solving the urgent logistical crisis in organ transplantation. Extending an organ's viability from a few hours to days transforms an emergency process involving private jets into a schedulable, cost-effective operation.

Behavioral economists predicted 'opt-out' systems would significantly increase organ donation. However, these systems show no improvement over 'opt-in' because the deceased's family is still consulted. Without explicit consent from their loved one, families often veto the default 'donation,' neutralizing the policy's intended effect.

Erik van den Berg highlights a critical paradox in the current standard of care for BK virus infections post-transplant. The only available intervention is lowering immunosuppression to fight the virus, but this simultaneously increases the probability that the patient's immune system will reject the newly transplanted organ.

Israel created a powerful incentive for organ donation by redesigning its allocation market. Citizens who register as donors receive priority on the transplant waiting list should they ever need an organ. This reciprocal system taps into self-interest for the common good and led to an estimated 100,000 new donor sign-ups in the small country.